Cue Biopharma, Inc.

Historical 13F Holders

Symbol
CUE
CUSIP
22978P106
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 22978P106 since 12/18/2024, newest first.

Filer % of Class Filed
Mark E. Strome 13G/A Amendment 2
4.99% 5/16/2025
Event 11/14/2022
Bleichroeder LP 13G/A Amendment 2
10.0% 3/21/2025
Event 3/19/2025
Slate Path Capital LP 13G/A Amendment 1
1.4% 2/14/2025
Event 12/31/2024
Bleichroeder LP 13G/A Amendment 1
10.0% 10/7/2024
Event 9/30/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 1 100 $55.00
2026 Q1 56 21.4 M $4.95 M
2025 Q4 49 21.8 M $6.67 M
2025 Q3 53 18.1 M $13.0 M
2025 Q2 48 17.4 M $11.9 M
2025 Q1 52 11.4 M $10.4 M
2024 Q4 59 11.8 M $12.8 M
2024 Q3 54 13.9 M $10.5 M
2024 Q2 81 13.9 M $17.3 M
2024 Q1 84 16.7 M $31.6 M
2023 Q4 90 15.2 M $40.0 M
2023 Q3 80 14.0 M $32.1 M
2023 Q2 81 13.8 M $50.5 M
2023 Q1 66 12.1 M $43.0 M
2022 Q4 66 12.9 M $36.8 M
2022 Q3 67 12.8 M $28.7 M
2022 Q2 81 14.1 M $35.0 M
2022 Q1 110 17.8 M $89.3 M
2021 Q4 101 16.6 M $188 M
2021 Q3 94 16.9 M $246 M
2021 Q2 96 18.6 M $216 M
2021 Q1 97 18.9 M $231 M
2020 Q4 105 19.3 M $242 M
2020 Q3 99 19.5 M $294 M
2020 Q2 104 16.0 M $393 M
2020 Q1 79 13.1 M $185 M
2019 Q4 66 10.8 M $172 M
2019 Q3 47 6.11 M $51.5 M
2019 Q2 38 4.50 M $40.5 M
2019 Q1 39 3.45 M $26.7 M
2018 Q4 38 3.36 M $15.8 M
2018 Q3 41 3.68 M $33.3 M
2018 Q2 40 3.18 M $37.7 M
2018 Q1 30 1.86 M $26.1 M